Results 101 to 110 of about 6,667 (221)

Exploring the tumor microenvironment in diffuse intrinsic pontine glioma: immunological insights and therapeutic challenges

Journal for ImmunoTherapy of Cancer
Diffuse intrinsic pontine glioma (DIPG) is a rare and highly aggressive pediatric brain tumor with a median survival of less than 12 months. The tumor arises in the pons, making surgical resection unfeasible and limiting treatment options to palliative ...
An Coosemans, Esther Hulleman, Bieke Van den Ende, Matteo Riva, Frederik De Smet, Sandra Jacobs   +5 more
doaj   +1 more source

What Epigenetics Teaches Us About Neuron–Glioma Interactions

BioEssays, Volume 47, Issue 9, September 2025.
Neuron–glioma interactions through the epigenetic lens. Rewiring of epigenetic mechanisms, including alterations in the enhancer landscape and 3D chromatin organization, allows glioma cells to sense and respond to neural signals. Targeting the epigenetic machinery that facilitates this neuron–glioma crosstalk provides a strategy to disrupt the neural ...
Chaitali Chakraborty, Itzel Nissen, Silvia Remeseiro   +2 more
wiley   +1 more source

Diffuse Intrinsic Pontine Glioma: A Therapeutic Challenge [PDF]

, 2016
Diffuse intrinsic pontine glioma (DIPG) is a tumor of the brainstem, specifically in the pons, accounting for 10–20% of all of central nervous system (CNS) tumors in children. Unfortunately, DIPG is the leading cause of death in children with CNS cancers.
Moser, Heloisa H., Nazarian, Javad, Packer, Roger J., Panditharatna, Eshini   +3 more
core   +2 more sources

DIPG-07. HIGH THROUGHPUT DRUG SCREENING IDENTIFIES POTENTIAL NEW THERAPIES FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs)

Neuro-Oncology, 2020
Abstract DIPGs are the most devastating of all brain tumors. There are no effective treatments, hence almost all children will die of their tumor within 12 months. There is an urgent need for novel effective therapies for this aggressive tumor.
Dannielle Upton, Santosh Valvi, Jie Liu, Nicole Yeung, Sandra George, Caitlin Ung, Aaminah Khan, Laura Franshaw, Anahid Ehteda, Han Shen, Isabella Orienti, Giovanna Farruggia, Christa Nath, Patrick Reynolds, Maria Tsoli, David Ziegler   +15 more
openaire   +1 more source

Multimodal management and outcome of pediatric and adolescent malignant central nervous system tumors: A single‐center retrospective study

Malignancy Spectrum, Volume 2, Issue 3, Page 128-139, September 2025.
Abstract Objective There is a paucity of real‐world evidence in the Indian context to address the outcome of primary brain tumors (PBTs) in children. This study aimed to describe the demographic profile, clinical characteristics, and histological features of PBTs based on the 2016 World Health Organization classification, assess the efficacy of ...
Priyadharshini Veeralakshmanan, Wesley M. Jose, Suhas Udayakumaran, M. R. Bindhu, Debnarayan Dutta, Kannan Rajesh, Sruthi Kavalagunta, Renjitha Bhaskaran, Nikhil K. Haridas, M. P. Rakesh, Keechilat Pavithran   +10 more
wiley   +1 more source

How I Approach Ethical Considerations for Pediatric Phase I CAR T‐Cell Trials

Pediatric Blood &Cancer, Volume 72, Issue 8, August 2025.
ABSTRACT Phase I trials of chimeric antigen receptor (CAR) T cells have shown remarkable promise in pediatric B‐cell malignancies. Such outcomes have shifted expectations for other phase I CAR T‐cell trials to have high response rates. The juxtaposition of high expectations, uncertain outcomes, and potential for life‐threatening toxicities raises ...
Sarah W. Peters, Sara K. Silbert, Elizabeth M. Holland, Annette Rid, Rayne H. Rouce, Christine Grady, Nirali N. Shah   +6 more
wiley   +1 more source

Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting

Advanced Materials, Volume 37, Issue 23, June 12, 2025.
CART cell therapy has proven effective for blood cancers but struggles with solid tumors due to diverse antigens and complex environments. Recent efforts focus on improving CAR design and validation platforms. Advances in protein engineering, machine learning, and organoid systems aim to enhance CAR‐T therapy against solid tumors.
Danqing Zhu, Won Joon Kim, Hyunjin Lee, Xiaoping Bao, Pilnam Kim   +4 more
wiley   +1 more source

H3 K27M-altered glioma and diffuse intrinsic pontine glioma:Semi-systematic review of treatment landscape and future directions [PDF]

H3 K27M-mutant diffuse glioma is a recently identified brain tumor associated with poor prognosis. As of 2016, it is classified by the World Health Organization as a distinct form of grade IV glioma.
Franceschi, Enrico, Geurts, Marjolein, Saratsis, Amanda M., van den Bent, Martin   +3 more
core   +1 more source

A Multicenter Phase II Trial of Nimustine Hydrochloride Administered via Convection‐Enhanced Delivery in Children With DIPG

Cancer Science, Volume 116, Issue 6, Page 1679-1690, June 2025.
The efficacy of the CED of nimustine hydrochloride in pediatric DIPG was evaluated. One‐year survival rate from the start of radiotherapy was 60%. The treatment strategy demonstrated potential efficacy. ABSTRACT Diffuse intrinsic pontine glioma (DIPG) is a very challenging‐to‐treat pediatric malignant tumor, with a median survival time of < 12 months ...
Ryuta Saito, Masayuki Kanamori, Yoshiki Arakawa, Yohei Mineharu, Yasuo Aihara, Kentaro Chiba, Toshihiro Kumabe, Ichiyo Shibahara, Yukihiko Sonoda, Kenichiro Matsuda, Manabu Kinoshita, Aya Sato, Fumiaki Takahashi, Teiji Tominaga   +13 more
wiley   +1 more source

Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma [PDF]

, 2014
Introduction Diffuse intrinsic pontine glioma (DIPG) is a malignant pediatric brain tumor associated with dismal outcome. Recent high-throughput molecular studies have shown a high frequency of mutations in histone-encoding genes (H3F3A and HIST1B) and ...
Ahsan, Sama, Ballester, Leomar Y., Eberhart, Charles G., Haffner, Michael C., Nazarian, Javad, Quezado, Martha, Raabe, Eric H., Rodriguez, Fausto J., Vaghasia, Ajay, Warren, Katherine E.   +9 more
core   +2 more sources